Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update

HAYA Therapeutics announced that the first cohort has been fully enrolled and dosed in its Phase 1 clinical trial of HTX-001, an investigational antisense oligonucleotide that targets the WISPER long non-coding RNA, according to the company. The molecule is designed to downregulate WISPER in cardiac…